---
schema_version: "secwatch.filing_event.v1"
accession: "0001723128-25-000033"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2025-07-21T23:59:59+00:00"
generated_at: "2026-05-18T05:10:28.497945+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Amneal prelim Q2 revenue $720M-$730M, adj EBITDA $180M-$185M; director resigns

## Summary
- Net revenue $720M-$730M (+3% YoY); income before taxes $45M-$56M vs $20M in Q2 2024.
- Adjusted EBITDA $180M-$185M (+13% YoY); gross leverage 3.8x, net leverage 3.7x.
- Director Emily Peterson Alva resigned July 16 after Amneal Group ownership dropped below majority of Class A common stock.
- Brekiya autoinjector approved for migraine/cluster headache; CREXONT uptake strong; biosimilar to XOLAIR BLA expected Q4 2025.
- Full year 2025 guidance expected to be met or exceeded based on year-to-date performance.

## SEC filing metadata
- accession: 0001723128-25-000033
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2025-07-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000172312825000033/0001723128-25-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000172312825000033/amrx-20250716.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001723128-25-000033
- JSON: https://secwatch.observer/filing/0001723128-25-000033.json
- Plain text: https://secwatch.observer/filing/0001723128-25-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.